BeyondSpring announced the appointment of Brendan Delaney to its Board of Directors, effective immediately. Mr. Delaney brings his significant expertise in commercial oncology drug launches. BeyondSpring's lead developmental asset, plinabulin, is currently under Priority Review by the U.S. Food and Drug Administration (FDA) for the prevention of chemotherapy-induced neutropenia (CIN) with a U.S. Prescription Drug User Free Act (PDUFA) action date of November 30, 2021. Mr. Delaney is expected to play an important role in the commercial launch planning for plinabulin and implementation, pending successful regulatory review. Mr. Delaney brings more than 25 years of global product strategy and launch experience to his role leading commercial organizations. Currently he serves as the Chief Commercial Officer of Constellation Pharma starting in January 2021.